Non-invasive Optical Imaging of Muscle Pathology in mdx Mice Using Cathepsin Caged Near-Infrared Imaging by Baudy, Andreas R. et al.
B The Author(s), 2010
Published Online: 27 July 2010 DOI: 10.1007/s11307-010-0376-z
Mol Imaging Biol (2011)13:462Y470
RESEARCH ARTICLE
Non-invasive Optical Imaging of Muscle
Pathology in mdx Mice Using Cathepsin Caged
Near-Infrared Imaging
Andreas R. Baudy,
1,2 Arpana Sali,
1 Sarah Jordan,
1 Akanchha Kesari,
1
Helen K. Johnston,
1,2 Eric P. Hoffman,
1,2 Kanneboyina Nagaraju
1,2
1Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA
2Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington DC, USA
Abstract
Purpose: To develop a reliable live-animal imaging method for monitoring muscle pathology in
mouse models of myopathy.
Procedures: A caged near-infrared Cathepsin B (CTSB) substrate, ProSense 680, is evaluated in
thedystrophindeficientmdxmice,agenetichomologueofDuchennemusculardystrophyviaoptical
imaging.
Results: We show high levels of infrared signal in dystrophic muscle relative to healthy muscle at
24 h post-injection. Imaging for CTSB presence revealed localization to inflammatory infiltrates
and regenerating muscle fibers. A time series myotoxin-induced muscle injury experiment
showed that CTSB activity and its mRNA levels peaked at the interface between inflammation
and myoblast fusion stage of recovery. Prednisone treatment in mdx mice resulted in decreased
CTSB activity and increased grip strength in forelimbs and hindlimbs.
Conclusions: Optical imaging of CTSB activity is an ideal method to sensitively monitor
inflammation, regeneration, and response to therapy in myopathic skeletal muscle.
Key words: Live optical imaging, Duchenne muscular dystrophy, mdx, Cathepsin B, Muscle
inflammation
Abbreviations: DMD, Duchenne muscular dystrophy; CTSB, Cathepsin B
Introduction
P
re-clinical trials in animal models of muscle disease are
a critical step in drug development. The most widely
used genetic and biochemical model for Duchenne muscular
dystrophy (DMD) is the mdx mouse [1–3]. However, it has a
relatively mild disease phenotype compared to the progres-
sion of disease seen in human patients, and so establishing
reliable and sensitive outcome measures for pre-clinical drug
trials using this model has been challenging.
The availability of live-animal imaging accelerates the
discovery of effective therapeutics in pre-clinical and clinical
trials because it can deliver a variety of useful patho-
physiological information in a longitudinal manner. Mag-
netic resonance imaging has been the primary imaging
modality successful at detecting muscle pathology, but it has
several limitations including cost, sensitivity for changes in
muscle tissue, speed of operation, and compliance of awake
children [4–6]. An alternative approach is the use of optical
probes, such as caged near-infrared enzyme substrates,
where imaging can be done using optical systems [7].
Statement of Significance: Currently, no optical-imaging technique exists
for surveying disease pathology of muscle in mouse models of myopathy.
Optical imaging offers high sensitivity of probe detection and ease of use,
making it an ideal method for monitoring muscle pathology and response to
therapy in a dystrophic mdx mouse model. We determined that ProSense
680, a caged near-infrared substrate for cathepsin B, was ideal for relaying
the status of both regeneration and inflammatory infiltration in skeletal
muscle. Prosense 680 was highly effective at optically distinguishing
inflammation in bl10 and mdx forelimb and hindlimb skeletal muscle, and
was effective at tracking damage in a myotoxin-induced model of muscle
injury.
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abnormalities, with increased susceptibility to contraction-
inducedmyofiberdamage,andbouts ofmyofiberdegeneration
and regeneration [1, 8]. Inflammatory cells are a feature of
dystrophic muscle, although the muscle is heterogeneous, with
different regions showing degeneration, regeneration, and
inflammation [9]. In fact, tissue heterogeneity is a major
limitation in using muscle biopsies to monitor efficacy of pre-
clinicalandclinicaltrials.Sinceregenerationandinflammation
are critical disease components in DMD, the identification of
an optical probe reflecting both of these processes would have
the potential to be a sensitive and reliable surrogate biomarker
relaying overall disease status within the muscle tissue.
The cathepsins are a family of 11 proteases that are
expressed in most cell types and generally become cleaved
and activated inlow pHenvironmentssuchasinthe lysosomes
[10]. Cathepsin B (CTSB) is a cysteine protease that has
previously been shown to be upregulated in DMD patient
muscle, primarily localizing to macrophage infiltrating areas
[11, 12]. CTSB is initially translated as an inactive 44 kDa
precursor protein, but can be activated into a mature 33 kDa
single-chain enzyme [13]. CTSB is highly upregulated in
activated fusing myoblasts and hypothesized to be a major
contributor to the process of extracellular matrix remodeling,
which is an essential step in muscle regeneration [14].
Here, we investigate the use of a CTSB substrate as a
live-animal imaging method to assess muscle pathology. We
show that optical imaging of CTSB enzyme activity using a
caged near-infrared substrate (ProSense 680) is capable of
effectively detecting muscle inflammation, regeneration, and
response to therapy in the mdx model via optical imaging.
Materials and Methods
Patient Expression Biopsies
DMD patient populations in this study were drawn from a referral
population. Flash-frozen muscle biopsies from patients with a
tentative diagnosis of muscular dystrophy were sent to the Dr.
Hoffman’s laboratory at Children’s National Medical Center, Wash-
ington DC. All biopsies were subjected to a standardized set of
biochemical and histological assays, including immunostaining for
dystrophin, alpha-sarcoglycan and merosin, and immunoblotting for
dystrophin and dysferlin. All samples were analyzed under CNMC
IRB protocol #2405 which has been reviewed and approved by the
Office for the Protection of Human Subjects at Children’s National
Medical Center. Dystrophin immunostaining and mRNA expression
profiling were performed as describedpreviously[15,16]andanalysis
criteria was set to only include patients over 2 years of age.
Mice
C57bl/10ScSn-Dmd
mdx/J (mdx) and control C57bl/10 (bl10) mice
were purchased from Jackson Laboratory (Bar Harbor, ME) and all
animal experiments were conducted in accordance with our IACUC
guidelines under approved protocols.
Optical Imaging
Five-week-old mdx and bl10 mice that underwent optical imaging
were first put under gas anesthesia using 4% isofluorane and 0.5 L/
min 100% oxygen, placed inside an Optix MX2 Imager (ART)
scanning chamber, and then anesthesia was maintained with 2%
isofluorane and 0.5 L/min oxygen through a nose cone to the mice.
The floor of the scanning chamber in which the mouse lies was
heated in order to maintain normal physiological body temper-
atures. Hair covering areas to be scanned was removed with Nair.
The plane of scanning was kept consistent between mice at the
level immediately above the forelimbs. Mice underwent intra-
peritoneal (I.P.) injection with 0.75 nmol or 1.5 nmol of ProSense
680 (VisEn Medical), both prepared in a total volume of 150 μl
phosphate-buffered saline (PBS). Areas of scanning were defined
with a polygonal selection tool, then a 670 nm excitation laser was
used for probe excitation at a 1.5-mm camera resolution in the
whole body scanning experiments (n=2/group), and at a 0.5-mm
camera resolution in skeletal limbs (n=3/group); emissions were
collected from a 700-nm long-pass filter. After scanning, the mice
were allowed to recover under 0.5 L/min oxygen. Optical-imaging
intensities from all experiments were normalized to account for
differences in scanning laser power, integration times, and scanning
area selected between mice using Optiview 2.0 software.
Histology and Immunofluoresence
Quadriceps from mdx mice were isolated and frozen in liquid
nitrogen-cooled isopentane, 8-μm frozen sections were prepared,
and unfixed cryosections from ProSense-injected mice were scanned
with a 635-nm excitation laser, and then subsequently stained with
Hematoxylin and Eosin (H&E). Notexin-injured gastrocnemious
muscles (see below) from bl10 mice were isolated and sectioned in
the same manner, blocked in 10% horse serum (HS) diluted in PBS
for 30 min, then incubated with Hoechst dye (Sigma Aldrich,
1:10,000), anti-laminin (Sigma Aldrich, 1:200), anti-embryonic
myosin heavy-chain (University of Iowa Hybridoma Bank, 1:200),
and anti-F4/80 (Serotec, 1:200) antibodies for 2 h at room temperature.
The sections were washed three times with PBS, and then Cy2 (Jackson
Immunoresearch, 1:500) and Alexafluor: 546, 633 (Invitrogen, 1:500)
secondary antibodies were prepared in 10% HS diluted in PBS and
appliedfor1h,thenthesectionswerewashedthreetimeswithPBS,and
mounted with permount (Fisher Scientific). The sections were
visualized using a LSM 510 confocal microscope (Zeiss).
Myotoxin Injury
mRNA profiles were analyzed for CTSB expression from a
previously published study in which cardiotoxin was administered
via intramuscular (I.M.) injection into the gastrocnemious muscle
of bl10 mice [16]. For the in vitro experiments notexin (Latoxin)
was prepared at a concentration of 4 μg/ml in 70 μl of 0.9% NaCl
and administered via I.M. injection into the right medial region of
the gastrocnemious muscle of bl10 mice, and 0.9% NaCl was
administered to the contralateral leg in the same region. Mice were
divided into post-notexin injection days 1, 3, 5, and 14 subsets (n=
3/group) and all received a single injection I.P. of 1.5 nmol
ProSense 680 24 h prior to imaging.
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Eight-week-old mdx mice were split into untreated and prednisone
treated groups (n=3/group); the treated group received prednisone in
time-release pellets (Innovative Research, 1 mg/kg), which were
implanted subcutaneously to establishcontinuous drug delivery. After
3 weeks of administration,allmice were scanned for baseline levels of
optical intensity, injected with 1.5 nmol of ProSense I.P, then 24 h
later,bothforelimbsandhindlimbswerescannedat0.5-mmresolution
and quantified using Optiview software. Grip strength was assessed
using a grip-strength meter (Columbusinstruments,Columbus,Ohio).
Five successful hindlimb- and forelimb-strength measurements were
recordedoveraperiodof2min.Thegrip-strengthmeasurementswere
collected in the morning hours over a 5-day period; the maximum
values of each day over the 5-day period were used for subsequent
analysis. Both grip strength and optical-imaging intensities were
normalized directly to body weight.
Statistical Analysis
Sample size calculations used a student’s t distribution to determine
the number of mice per group needed to detect a significant
difference between untreated and prednisone chronic treatment. The
same method was used to determine sample sizes necessary to
detect a significant difference in normalized forelimb/hindlimb
measurements. All calculations assumed an alpha level of 0.05 and
a power level of 80%.
Results
Cathepsin B Shows High Expression in Duchenne
Muscular Dystrophy Patient Muscle
Thirteen muscle biopsies from DMD patients and six biopsies
from non-dystrophic control patients were evaluated by micro-
array transcriptional analysis, then queried for four CTSB
probe sets, which represented the entire range of CTSB
transcripts (see Supplementary Fig. 1 online). Twelve of the
13 DMD biopsies had upregulated CTSB levels in at least one
of the four probe sets, and the majority of biopsies had
upregulated CTSB levels inat least three of the four probe sets.
DMD patient biopsy three was the primary outlier in the
analysis, since CTSB was entirely downregulated. Five of the
Fig. 1. CTSB activity and localization in limb muscles 24 h post-Prosense 680 injection. Optical imaging performed at 0.5 mm
resolution of the limb muscles in mdx and bl10 mice (a). CTSB was activated 3.15-fold more in mdx forelimb compared to bl10
and 1.85-fold more in hindlimb (Student’s t test, showing standard error of the mean, **p value=0.0017, ***p value=0.0001).
Frozen cross-sections of quadriceps muscle taken from mdx mice were visualized in the near-infrared (green), then
subsequently stained with H&E (b). CTSB signal was highly specific to areas containing regenerating fibers, illustrated by white
arrows, and inflammatory foci illustrated by black arrow.
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for CTSB transcript, with only control patient biopsy six
showing upregulation.
I.P. Injection of Caged Near-Infrared CTSB
Substrate Detects Cathepsin Activity in Dystrophic
Muscle
ProSense 680 is a small peptide substrate for activated
CTSB [17]. When cleaved by the CTSB enzyme, two
caged fluorophores are released, with peak excitation at
680 nm, and emission in the near-infrared range
(700 nm). Intraperitoneal injection of 1.5 nmol or
0.75 nmol ProSense 680 was done in 5-week-old wild-
type bl10 and dystrophin-deficient mdx mice. Serial
optical whole body scanning at a 1.5-mm camera step
resolution demonstrated near-infrared signal in the liver
and bladder at 6 h that was similar between dystrophic
and control mice (see Supplementary Fig. 2a online).
Signal corresponding to limb muscle was observed more
specifically in the dystrophic mice with a plateau at 24–
48 h. The average total limb photon intensity was
quantified for both bl10 and mdx mice that were injected
with either 1.5 or 0.75 nmol over time (see Supplemen-
tary Fig. 2b online).
Based on this time course data, all further experiments
were performed using the 1.5 nmol dose of ProSense,
with scanning performed 24 h after injection. A group of
age matched (5-week-old) mdx a n db l 1 0w i l d - t y p em i c e
(n=3 per group) were injected with 1.5 nmol ProSense
and a single scan was performed of solely the forelimb
and hindlimb. We found significant increases in CTSB
photon count intensity in the mdx forelimb (3.1-fold
increase) relative to bl10, as well as in the hindlimb (1.9-
fold increase) (Fig. 1a). After imaging, mice were euthanized
then cryosections of their quadriceps were exposed for near-
infrared signal, subsequently stained with H&E, and both
images superimposed. CTSB activity was localized to both
centrally nucleated regenerating fibers (white arrows), as well
as inflammatory cells (black arrow)( F i g .1b).
Myotoxin-Induced Regeneration Stimulates CTSB
Transcription, with Peak at Myoblast/Myotube
Transition
Zhao et al. [18] previously had investigated myofiber
damage in the gastrocnemious of bl10 mice using micro-
array transcriptional analysis of myotoxin-damaged tissues.
CTSB-transcript activity significantly increased between
days 2–6 ,w i t hap e a ka td a y3( F i g .2a). We followed-
Fig. 2. CTSB is strongly expressed on mRNA and activated at protein levels in myotoxin-damaged muscle. bl10 mice were
injured with I.M. injection of myotoxin into the gastrocnemious, and microarray expression analysis was subsequently
performed. a) Analysis of two representative CTSB probes (92256_at and 95608_at, shown as an average) revealed slight
mRNA upregulation at day 1, with peak levels at day 3 and a decline back to near baseline by day 14. (Student’s t test, showing
standard error of the mean, *pvalue of day 3 and day 5=0.0127, for day 1 and day 5=0.0175; **p value for day 5 and day 14=
0.0035, for day 1 and day 3=0.0060). b) CTSB caged optical imaging in the hindlimbs of myotoxin injured bl10 mice revealed a
drastic increase of CTSB activity atday 1,witha peak at day3, andresolutionbyday14 (Student’s t test, showing standarderrorof
the mean, *p value day 1=0.0303, **p value day 3=0.0046, day 5=0.0012).
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administering I.M. injections of saline into the left leg
gastrocnemious and myotoxin in the right leg gastro-
c n e m i o u so fa l lm i c e ,w h i c hw e r et h e ni m a g e do nd a y s1 ,
3, 5, and 14 post-injection. A rapid increase of activated
CTSB levels in the injured leg was observed at post-
myotoxin injection day 1, followed by a peak at day 3,
and resolution of activity by day 14 (Fig. 2b). Injured
gastrocnemious muscles taken from day 5 exhibited
inactive precursor CTSB co-localization primarily to
macrophages (Fig. 3), whereas activated CTSB was
observed both in macrophages and in regenerating fibers
(Fig. 4).
Therapeutic Response can be Successfully
Evaluated in the mdx Mouse with CTSB Imaging
We tested the sensitivity of our method to detect therapeutic
benefits induced by prednisone, the current standard of
treatment for DMD patients, in the mdx model. A prednisone
pellet was placed subcutaneously for continuous dosing for a
total of 3 weeks, and then CTSB optical imaging and
grip-strength analysis were performed at endpoint (Fig. 5).
We observed a 49.7±10.9% reduction of CTSB signal in the
forelimbs and 25.9±9.7% reduction in hindlimbs (Fig. 5a), as
well as a 14.7±2.2% increase in forelimb strength and a 21.9±
2.5% increase in hindlimb strength (Fig. 5b).
Statistical Analysis Demonstrates Excellent
Sensitivity in Detecting Strain and Drug
Treatment Differences
Statistical calculations based on the mean and standard
deviations predicted that the assay is highly sensitive in
detecting differences between mdx and bl10 strains, with
only one mouse required per group to detect differences in
the forelimbs, and three mice required per group to detect
differences in the hindlimbs (Table 1). The sensitivity for
monitoring prednisone-induced drug benefits was also
excellent for detecting differences in the forelimbs, requiring
only two mice per group, but more modest in the hindlimbs,
requiring six mice per group (Table 2).
Discussion
Our goal was to define an optical-imaging method that could
comprehensively capture muscle pathology in the mdx
model, so as to improve the effectiveness of monitoring
therapeutic intervention in pre-clinical studies. Since we
Fig. 3. Inactive CTSB precursor protein localizes to macrophage cytosol. Gastrocnemious muscles taken 5 days post-notexin
injection demonstrated the presence of inactive CTSB within the cytosol of macrophages (white arrows).
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post-notexin injection revealed co-localization of ProSense, which detects activated CTSB, within newly regenerating fibers
(eMyosin), as well as within the cytosol of infiltrating monocytes (white arrow).
Fig. 5. Prednisone decreases CTSB activity, and correlates with functional improvement. a) Prednisone was released
continuously in mdx mice by placement of a subcutaneous pellet (1 mg/kg) for a total of 3 weeks, and then imaged at baseline
without ProSense injection and 24 h after injection. b) Grip strength of untreated and mice receiving continuous prednisone was
measured after 3 weeks of treatment in the forelimbs and hindlimbs. Student’s t test, showing standard error of the mean, ***p
value of forelimbs=0.0006, *p value of hindlimbs=0.0497.
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processes possible, we selected CTSB as our enzymatic
marker since it reports on multiple key pathological events
relevant to muscle injury. CTSB is secreted by macrophages
and activated myoblasts to support the clearance of
degenerating injured fibers, as well as promote regeneration
via signaling for myoblast fusion [14, 19, 20]. It has already
been demonstrated that CTSB protein levels are upregulated
in DMD patients as well as in mouse xenograft models, and
we further validate this by showing that four encompassing
probe sets of the CTSB transcript population are also
strongly upregulated (see Supplementary Fig. 1 online)
[11, 12]. From the three DMD biopsies that demonstrated
the lowest relative levels of CTSB (DMD 3, DMD 4, DMD
11), all had mild histological features such as larger fiber sizes,
and minimal amounts of degenerating and regenerating fibers.
ProSense 680 is a commercial near-infrared probe from
VisEn Medical and is highly specific for activated CTSB
activity. It is normally optically quiescent, but upon reaching
areasofactivatedCTSB,itbecomesenzymaticallycleavedand
emits an intense near-infrared signal. We injected a single
0.75-nmolor1.5-nmoldoseofProSense680I.P.to5-week-old
mdx and bl10 mice; this age group was selected because mdx
mice show peak fiber degeneration and regeneration between
4–10 weeks (see Supplementary Fig. 2 online). Sequential
whole body 1.5-mm camera resolution infrared imaging
revealed that both bl10 and mdx mice had active CTSB in the
liver and bladder; however, activity was consistently detected
at higher levels in mdx limbs compared to bl10 at the 1.5-nmol
dose. ProSense levels declined over the course of 7 days,
eventually reaching near baseline values, indicating clearance
of the probe.
Having determined the peak dose and time point to detect
differences in CTSB activity between mdx and bl10 limb
muscle, we performed high-resolution camera (0.5 mm) imag-
ingofonlytheforelimbsandhindlimbs24hlater(Fig.1a).The
CTSB levelswereincreased inmdx tissueoverbl10, indicating
higher levels of inflammation and regeneration. Moreover, the
higher levels of CTSB activity in mdx forelimbs over bl10
forelimbs (3.1-fold increase) compared to mdx forelimbs over
bl10 hindlimbs (1.9-fold increase) suggested more relative
pathology in the forelimbs. Interestingly, this finding is
supported by functional grip-strength studies, which clearly
demonstrate a greater deficit in grip strength between mdx and
bl10 mice in the forelimbs over the hindlimbs [21]. Taken
together, this suggests that CTSB activity could be inversely
related to grip strength. Cryosectioning of quadriceps taken
from mdx mice that had been injected with ProSense revealed
CTSB activity localized specifically to areas of myofiber
remodeling (inflammation and regeneration) (Fig. 1b).
We have defined a sensitive method for detecting
dystrophic pathology; we therefore wanted to extend its
applicability for detecting broader types of muscle injury.
Myotoxins such as cardiotoxin and notexin are isolated from
snake venom and are highly damaging to myofibers. Intra-
muscular injection of myotoxins has been shown to induce
controlled muscle injury, and, therefore, is useful for
studying stage-specific processes in muscle damage and
regeneration [22, 23]. Cardiotoxin injection into the gastro-
cnemious of bl10 mice followed by microarray transcrip-
tional profiling and querying for CTSB revealed that mRNA
levels of the enzyme were highest between days 2–5, post
injury, with a peak at day 3 (Fig. 2a). Mice that received an
intramuscular notexin injection into their right gastrocnemious
and were imaged showed an extraordinary amount of activated
CTSB at day 1 (Fig. 2b); the levels observed here were more
than double that of the mdx hindlimb activity shown earlier,
demonstrating the severity of acute damage. The peak amount
of activated CTSB occurred at day 3, which paralleled mRNA
production.Byday14,CTSBapproachedcomparablelevelsto
the saline-injected leg, reflecting the completion of successful
myoblast fusion and clearance of infiltrating inflammatory
cells. The saline-injected contralateral control leg showed a
similar progression in CTSB activity over time, with a peak
amount of damage also occurring at day 3, but at much lower
levels.
Table 1. Sample size calculations comparing forelimb and hindlimb between mdx and bl10 mice
Measurement mdx bl10 N needed per group to
detect a significant difference between mice strains
Mean total photon counts/mm
2±SD Mean total photon counts/mm
2±SD
Forelimb 8,048.33±977.08 2,645.67±1,129.37 1
Hindlimb 14,866.67±2,920.73 8,354.17±2,360.29 3
Table 2. Sample-size calculations comparing untreated with prednisone
Measurement Untreated Prednisone N needed per group to detect a
significant treatment difference
N Mean total photon counts/mm
2±SD N Mean total photon counts/mm
2±SD
Forelimb 3 7,005.0±977.8 3 3,521.4±911.6 2
Hindlimb 3 12,481.7±1,937.7 3 9,240.2±1,722.8 6
Mean and standard deviations were calculated from the forelimb and hindlimb data in Fig. 1a and Fig. 5a and the number of mice needed per group in order to
detect significant differences between strains, and for prednisone treatment was calculated
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from Notexin-injured mice, we found co-localization of the
CTSB inactive precursor protein exclusively in infiltrating
macrophages, as demonstrated by co-localization between
CTSBantibodyandF4/80(Fig.3).Interestingly,uponimaging
of ProSense and embryonic Myosin, heavy-chain, active
CTSB was also detected in both infiltrating monocytes and
regenerating fibers (Fig. 4). These results substantiate our
findings in the quadriceps of 5-week-old mdx mice, in that
active CTSB is highly localized to areas of myofiber damage,
and demonstrate its association with muscle repair, inflamma-
tory, and remodeling processes.
The only effective treatment for DMD discovered to date
is glucocorticoids, such as prednisone [24]. Granted that
glucocorticoids are ridden with numerous long-term treat-
ment side effects, they are known to reduce both inflamma-
tion and excessive muscle degeneration in the short term.
We tested our caged CTSB optical method to gauge
prednisone’s therapeutic effects by administering it for a
total of 3 weeks to mdx mice in a continuous release pellet,
and then performed functional grip-strength tests and optical
imaging (Fig. 5). Significant decreases of CTSB activity
were measured in both the hindlimbs and forelimbs of
prednisone-treated mice, and were accompanied by increases
in grip strength (Fig. 5). These data clearly indicate that a
decrease in CTSB activity is reflected in an increase in grip-
strength measurements at the functional level. The assay
described is highly sensitive and specific, requiring only a
few animals to see differences between affected and wild-
type, or between drug-treated and control dystrophic animals
(Tables 1 and 2).
Overall, we found that, under the conditions described,
ProSense 680 is a highly effective tool for evaluating in
vivo assessments of muscle damage, and as a measure of
efficacy for drugs designed to reduce inflammation and
damage in dystrophic muscle in pre-clinical trials. In the
clinic, Optical imaging is beginning to be used more
frequently since it doesn’t depend on radioactive sub-
stances or ionizing radiation, yet provides functional data
in a cost-effective manner [25, 26]. The detection of
probes using optical imaging also exhibits excellent
sensitivity (nmol–pmol range). However, in order to
obtain clinically useful results, optical systems and their
corresponding probes need to be optimized for monitoring
deep tissues due to constraints related to light trans-
mittance and scattering. It would be interesting to see if
more powerful therapeutic treatments (e.g., exon skipping,
adenovirus gene replacement) could be evaluated using
this methodology, and further, if this technology could be
applied to DMD patients to gather rapid information on
disease progression.
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